{"id":"NCT02220725","sponsor":"Portola Pharmaceuticals","briefTitle":"A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban","officialTitle":"A Phase 3 Randomized, Double-blind, Placebo-controlled Study in Older Subjects to Assess Safety and the Reversal of Rivaroxaban Anticoagulation With Intravenously Administered Andexanet Alpha","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05","primaryCompletion":"2015-08","completion":"2015-08","firstPosted":"2014-08-20","resultsPosted":"2018-09-25","lastUpdate":"2023-02-10"},"enrollment":80,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bleeding"],"interventions":[{"type":"BIOLOGICAL","name":"Andexanet","otherNames":["Andexanet alpha","PRT4445"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Andexanet 800mg bolus (Part I)","type":"EXPERIMENTAL"},{"label":"Andexanet 800mg + 960mg (Part II)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Rivaroxaban.","primaryOutcome":{"measure":"Efficacy: Percent Change From Baseline in Anti-fXa Activity at the Nadir (Parts I and II)","timeFrame":"Baseline to +2 minutes or +5 minutes following the end of andexanet/placebo bolus (Part I), or 10 minutes prior to end of andexanet/placebo continuous infusion or 5 minutes after the end of andexanet/placebo continuous infusion (Part II)","effectByArm":[{"arm":"Placebo (Part I)","deltaMin":-18.39,"sd":14.662},{"arm":"Andexanet (Part I)","deltaMin":-92.22,"sd":10.697},{"arm":"Placebo (Part II)","deltaMin":-44.75,"sd":11.749},{"arm":"Andexanet (Part II)","deltaMin":-96.72,"sd":1.838}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG002 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["26559317"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":14},"commonTop":["Infusion Related Reaction","Muscle Spasms","Constipation"]}}